18:08 , Feb 28, 2018 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Multiple sclerosis (MS) Mouse studies suggest the PKCE activator bryostatin-1 could help treat MS. In the experimental autoimmune encephalomyelitis (EAE) mouse model of MS, administration of bryostatin-1 at the onset of muscle weakness decreased...
00:18 , Dec 20, 2017 |  BC Extra  |  Company News

Management tracks: Intellia, Spectrum

Gene editing company Intellia Therapeutics Inc. (NASDAQ:NTLA) said CEO Nessan Bermingham will resign, effective Jan. 1. EVP of R&D John Leonard will succeed Bermingham. Hematology and cancer company Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) said CEO Rajesh Shrotriya...
16:54 , Oct 17, 2017 |  BC Innovations  |  Distillery Techniques

Chemistry

TECHNOLOGY: Synthetic chemistry A simplified multi-step method could enable scalable synthesis of the PKC modulator bryostatin-1 and its analogs to treat neurological diseases, HIV/AIDS and cancer. The method involved the total synthesis of bryostatin-1 or...
21:02 , May 5, 2017 |  BC Week In Review  |  Clinical News

Neurotrope reports mixed Ph III AD data for Bryostatin-1

Neurotrope Inc. (NASDAQ:NTRP) said top-line data from the modified intent-to-treat (mITT) population (n=135) of the double-blind, U.S. Phase II NTRP-101-202 trial to treat moderate to severe Alzheimer’s disease showed that 20 μg IV Bryostatin-1 failed...
23:01 , May 1, 2017 |  BC Extra  |  Clinical News

Neurotrope hammered after Alzheimer's readout

Neurotrope Inc. (NASDAQ:NTRP) plummeted $11.84 (63%) to $6.97 after announcing results of a Phase II study of Bryostatin-1 to treat Alzheimer's disease. On the primary endpoint, which measured improvements in Severe Impairment Battery (SIB) scores...
20:31 , Feb 3, 2017 |  BC Week In Review  |  Company News

Stanford, Neurotrope deal

Stanford granted Neurotrope exclusive, worldwide rights to a process that allows for the accelerated synthesis of the company's bryostatin-1. Neurotrope said obtaining natural bryostatin-1 includes a lengthy purification process and that the synthetic version has...
20:29 , Nov 23, 2016 |  BC Week In Review  |  Clinical News

Bryostatin-1: Completed Ph II enrollment

Neurotrope completed enrollment of 148 patients in a double-blind, placebo-controlled Phase II trial evaluating 20 and 40 µg IV Bryostatin-1 given as 7 doses over 12 weeks. Neurotrope Inc. (OTCQB:NTRP), Newark, N.J.  Product: Bryostatin-1  Business: Neurology  Molecular target: Protein...
21:27 , Nov 18, 2016 |  BC Week In Review  |  Financial News

Neurotrope completes private placement of common stock and warrants

Neurotrope raised $20.2 million through the sale of 100.9 million shares at $0.20 in a private placement to new and existing investors. Investors also received five-year warrants to purchase up to 100.9 million shares at...
07:00 , Aug 22, 2016 |  BC Week In Review  |  Clinical News

Bryostatin-1: Phase IIb amended

Neurotrope submitted to FDA an amended protocol for an ongoing double-blind, placebo-controlled, U.S. Phase IIb trial of 20 and 40 ug IV Bryostatin-1 given as 7 doses over 12 weeks in about 150 patients to...
08:00 , Feb 1, 2016 |  BC Week In Review  |  Clinical News

Bryostatin-1: Phase IIb started

Neurotrope began a double-blind, placebo-controlled, U.S. Phase IIb trial to evaluate 10, 20 and 40 ug IV Bryostatin-1 over 24 weeks in about 150 patients. In the first 12-week treatment period, patients will receive 20...